Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis

被引：0
作者：
B. Jönsson
O. Ström
J. A. Eisman
A. Papaioannou
E. S. Siris
A. Tosteson
J. A. Kanis
机构：
[1] Stockholm School of Economics,Geriatrics and Medicine
[2] McMaster University,undefined
来源：
Osteoporosis International | 2012年 / 23卷
关键词：
Public Health; Osteoporosis; Relative Risk; Base Case; Case Scenario;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2063 / 2065
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    E. Söreskog
    I. Lindberg
    J.A. Kanis
    K.E. Åkesson
    D. Willems
    M. Lorentzon
    O. Ström
    P. Berling
    F. Borgström
    [J]. Osteoporosis International, 2021, 32 : 585 - 594
  • [22] Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm
    Kim, K.
    Svedbom, A.
    Luo, X.
    Sutradhar, S.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (01) : 325 - 337
  • [23] Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
    M. Hiligsmann
    J.-Y. Reginster
    [J]. Osteoporosis International, 2019, 30 : 649 - 658
  • [24] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [25] Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
    Min, Yong-Ki
    [J]. ENDOCRINOLOGY AND METABOLISM, 2015, 30 (01) : 19 - 26
  • [26] Clinical use of denosumab for the treatment for postmenopausal osteoporosis
    Lewiecki, E. Michael
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) : 2807 - 2812
  • [27] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
    Lewiecki, E. Michael
    [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 79 - 91
  • [28] Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients
    Morizio, Paige
    Burkhart, Jena I.
    Ozawa, Sachiko
    [J]. ANNALS OF PHARMACOTHERAPY, 2018, 52 (10) : 1031 - 1041
  • [29] The cost-effectiveness of risedronate in the treatment of osteoporosis:: an international perspective
    Borgstrom, F.
    Carlsson, A.
    Sintonen, H.
    Boonen, S.
    Haentjens, P.
    Burge, R.
    Johnell, O.
    Jonsson, B.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (07) : 996 - 1007
  • [30] Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis
    Hiligsmann, M.
    Ben Sedrine, W.
    Bruyere, O.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 (08) : 2291 - 2300
12345